Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • merck

    Tag: Merck

    You Searched For "merck"
    Merck KEYTRUDA gets USFDA priority review for its Second Application

    Merck KEYTRUDA gets USFDA priority review for its Second Application

    Medical Dialogues Bureau9 April 2020 9:00 AM IST
    Kenilworth: Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has accepted and...
    Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer

    Merck gets Japanese nod for TEPMETKO(tepotinib) for non-small cell lung cancer

    Medical Dialogues Bureau28 March 2020 11:45 AM IST
    TEPMETKO is the first regulatory approval globally for an oral MET inhibitor indicated for the treatment of advanced NSCLC harboring MET gene...
    Merck Announces positive results for Gefapixant  Phase 3 Trial to treat Chronic Cough

    Merck Announces positive results for Gefapixant Phase 3 Trial to treat Chronic Cough

    Medical Dialogues Bureau21 March 2020 10:15 AM IST
    Kenilworth: Merck, known as MSD outside the United States and Canada, has announced top-line efficacy results from two ongoing pivotal Phase 3...
    Merck, AMCM collaborates for 3D Printing of Tablets

    Merck, AMCM collaborates for 3D Printing of Tablets

    Medical Dialogues Bureau1 March 2020 10:30 AM IST
    3D printing allows for API (active pharmaceutical development) formulation to be scalable while avoiding costly reformulations throughout the entire...
    Merck Keytruda, Chemotherapy combo meets endpoint for first-line treatment of Breast Cancer

    Merck Keytruda, Chemotherapy combo meets endpoint for first-line treatment of Breast Cancer

    Medical Dialogues Bureau18 Feb 2020 10:15 AM IST
    New Delhi: Merck known as MSD outside the United States and Canada, recently announced that the pivotal Phase 3 KEYNOTE-355 trial investigating...
    Merck introduces BrightLab, cloud-based instrument connectivity platform for research scientists

    Merck introduces BrightLab, cloud-based instrument connectivity platform for research scientists

    Medical Dialogues Bureau15 Feb 2020 10:15 AM IST
    Germany: Merck, a leading science and technology company, recently introduced its BrightLab cloud-based inventory management and instrument...
    Merck to spin-off  biosimilar drugs business to focus on Keytruda

    Merck to spin-off biosimilar drugs business to focus on Keytruda

    Medical Dialogues Bureau7 Feb 2020 9:15 AM IST
    Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company...
    Mercks antibacterial med Dificid Gets FDA nod in Pediatric Indication

    Merck's antibacterial med Dificid Gets FDA nod in Pediatric Indication

    Medical Dialogues Bureau30 Jan 2020 3:50 PM IST
    Merck & Co., Inc announced that the FDA has granted approval to its new drug application ("NDA") and a supplemental NDA (sNDA) for its...
    Drugmajors slash prices by 53pc for China bulk-buy program eligibility

    Drugmajors slash prices by 53pc for China bulk-buy program eligibility

    Medical Dialogues Bureau20 Jan 2020 10:00 AM IST
    Beijing: Global pharmaceutical majors and generic drugmakers chopped by 53% on average prices of some of their off-patent products in the latest...
    MSD India appoints Rehan A Khan as Managing Director

    MSD India appoints Rehan A Khan as Managing Director

    Medical Dialogues Bureau10 Jan 2020 12:04 PM IST
    Rehan A Khan was also a board member and advisor to several impacts led Private Equity funds and to healthcare companies in Africa, India, and...
    Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations

    Merck Ebola vaccine Ervebo to be available at lowest access price for poor nations

    Medical Dialogues Bureau24 Dec 2019 9:00 AM IST
    The vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that...
    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial

    Medical Dialogues Bureau3 Nov 2019 9:00 AM IST
    Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to...
    Next

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 13 Oct 2022 5:14 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier
    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

    © 2025 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok